- Exclusive: Income tax now begins investigation in Axis Mutual Fund case; 12 fund managers in India now within its radar: Sources
- Dalal Street Corner: Sell-off IT, FMCG, metal force market to close in red for 2nd day; what should investors do on Wednesday?
- Grasim Industries Q4 results 2022: PAT up 55% YoY, net sales rises by 18%; company recommends Rs 5 dividend
- Government allows duty-free import of 20 lakh tn per year of crude soyabean, sunflower oil; applicable for FY23, FY24
- SEBI allows MFs to launch passive ELSS, debt-based ETF schemes; Zee Business decodes what it means for investors
Windfall For Top 20 Firms in Pharma Inc
Updated: October 29, 2018 14:51 pm
After two consecutive years of single-digit expansion, big Indian drug firms are expected to return to double-digit growth in the currect fiscal aided by recovery in US sales, weakening of the rupee and revival of domestic demand, ratings agency Crisil said.
